The Latest Cardiac and Vascular News
Firibastat efficacy non-significant versus placebo The REFRESH study and the development of firibastat in cardiology have been stopped Cash of 11 million euros allotted to the development of new innovative treatments, after discontinuation of the REFRESH study PARIS, Oct. 28, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical […]
PARIS, Oct. 06, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products that act directly on the brain to treat resistant/difficult to treat hypertension and heart-failure, today announces the publication of an initiation report by Bryan […]
PARIS, Oct. 05, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products that act directly on the brain to treat resistant/difficult to treat hypertension and heart-failure, today published its first half 2022 results. Jean-Philippe Milon, CEO […]
PARIS, June 27, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat hypertension and heart failure, today announces the appointment of new members of its Scientific Advisory Board. Professor George L. Bakris […]
PARIS, May 09, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat hypertension and heart failure, announces today that it has recruited all planned patients in its phase III pivotal study FRESH, […]
PARIS, May 04, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat difficult-to-treat/resistant hypertension and heart failure, announces it is strengthening its leadership team with the appointment of Sarah Merlen-Boulenger as Head […]
PARIS, April 28, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products that act directly on the brain in order to address difficult-to-treat/resistant hypertension and heart failure, today reported its full year 2021 results. […]
Quantum Genomics has equipped itself with new financial means to pursue the development of firibastat and explore new therapeutic fields based on the patented technology platform built around BAPAIs Quantum Genomics is taking this opportunity to strengthen and expand its shareholder structure PARIS, April 27, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth […]
Launch of capital increase of approximately €15 million for institutional investors with cancellation of the pre-emptive subscription right A minimum of €12 million subscription commitments received from institutional investors, including €10 million from Otium Capital Raise to coincide with pharmaceutical company Julphar acquiring stake in Quantum Genomics via reserved capital […]
PARIS, March 31, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat resistant/hard-to-treat hypertension and heart failure, announced the publication of a new scientific article reporting the efficacy of its second drug-candidate, […]
